Medios AG earnings date
Want to see DE:ILM1 full AI Analyst Report?
Medios AG (ILM1) Q3 2026 Earnings Report
DE:ILM1 Q3 2026 EPS Results
- Actual EPS
- EUR 0.17
- Consensus EPS
- EUR 0.26
- Beat/Miss
- Missed by -EUR 0.09
- One Year Ago EPS
- EUR 0.29
DE:ILM1 Q3 2026 Revenue Results
- Actual Revenue
- EUR 558.11M
- Expected Revenue
- EUR 551.20M
- Beat/Miss
- Beat by +EUR 6.91M
- YoY Revenue Growth
- +3.68%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/10/2026
- Time
- Before Open
- Conference Call
- Tuesday, November 10, 2026
Medios AG's next earnings date is estimated for March 31, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call had a positive overall tone. Revenue growth was broad-based, patient-specific therapies showed clear margin improvement, operational-efficiency measures were producing savings, financing was strengthened, and full-year guidance was confirmed. These positives outweighed ongoing pricing pressure, lower margins and earnings, weaker operating cash flow, elevated taxes, and regulatory uncertainty.
Medios confirmed guidance for 2026 in terms of EBITDA and sales for the fourth quarter and full year 2026, while expecting to be on the lower side of the EBITDA corridor and implying a little more than EUR 21 million for Q4 EBITDA pre; the guidance excludes Caelo and did not include the approx EUR 1.2 million Hilfstaxe impact, with Avanti Medios! expected to deliver EUR 5 million for 2026, of which 2.7 are already now -- or 2.5 are already now realized. Operating cash flow is expected to be around EUR 40 million, while EUR 50 million plus/minus is the normal cash flow expected in a normal year and EUR 40 million, EUR 45 million reflects eliminating this year’s impacts; this is not a guidance. CapEx is expected to remain around EUR 10 million in a year, the tax rate next year is expected to be below 40%, with something between 35% to 40% max, and Medios reiterated its ambition to increase the business from EUR 2.1 billion to EUR 3.1 billion until 2031, with about EUR 325 million planned for M&A.
- Broad-Based Revenue GrowthRevenue for the first 9 months reached EUR 1.633 billion, an increase of 6.7% year over year, with all business segments contributing to growth. Q3 revenue was EUR 558 million.
- 2026 Guidance ConfirmedManagement confirmed its adjusted 2026 sales and EBITDA guidance despite the Hilfstaxe adjustment. The company expects to be on the lower side of the EBITDA corridor.
- Avanti Medios! Program Delivering SavingsThe operational efficiency program is on plan. Management expects EUR 5 million of savings in 2026, with EUR 2.5 million already realized and all remaining activities identified and underway.
- Patient-Specific Therapies Margin RecoveryPatient-specific therapies revenue increased 8.4% for the first 9 months. German patient-specific therapies returned to a double-digit EBITDA pre margin, while Q3 EBITDA reached approximately EUR 6.3 million, representing a 10% margin.
- Pharmaceutical Supply Revenue GrowthPharmaceutical supply revenue increased 6.8% for the first 9 months. Q3 revenue was EUR 455 million, up 3.6% versus the prior-year quarter, with management reporting first improvements in the pricing environment.
- International Business Adjusted Growth and Cost ActionsReported international revenue growth was 4.1%, but management said growth would have been approximately 7.5% to 7.6% excluding divested non-core activities. Q3 international EBITDA pre margin was 14.9%, and restructuring and cost-efficiency actions were initiated across Magis Pharma, Breda and Oostrum.
- Capacity and Operational LeverageMedios has five laboratories and ready-to-scale capacity within its existing footprint. Following the closure of the Aschaffenburg site, all customers were transferred to other locations, capacity utilization increased, and this was achieved without increasing operational personnel.
- Patient ReachThe company supported 365,000 patients during the first 10 months of the year.
- Strategic Caelo Acquisition and IntegrationMedios completed the strategic acquisition of Caelo in the Compounding Essentials business and is working on team integration and synergies through an integration management office. The 2026 guidance still excludes Caelo.
- Next Level 2031 Growth AmbitionManagement reiterated its ambition to increase the business from EUR 2.1 billion to EUR 3.1 billion by 2031 through profitable organic and inorganic growth, with the main growth contribution expected from compounding.
- Financing Structure StrengthenedThe RCF was increased from EUR 100 million to EUR 125 million, with a further EUR 25 million extension option available. The maturity of tranche B was extended to 13 November 2031.
- Strategic and Digital Initiatives On TrackThe implementation of the two-segment structure is progressing, and the SAP S/4HANA rollout for Medios Pharma remains on track to start in January, with the system expected to be operational in the first quarter of 2027. The company is also advancing its digitalization roadmap and operational-excellence initiatives.
- Organic Growth and M&A PipelineMedios is pursuing new customers, product development, capacity utilization and market trends to drive organic growth. Management said M&A will remain focused on healthy pricing and identifiable synergies.
- Share Buybacks Remain a Preferred Capital Allocation OptionManagement reiterated that share buybacks are a preferred option in the current environment. Buyback and share-cancellation topics remain under investigation and discussion, while the company also intends to retain flexibility for growth investments and selected M&A.
- No Goodwill Impairment ExpectedManagement stated that it does not see a risk of goodwill impairment at year-end 2026 and does not expect a material reduction in impairment-test headroom.
- Lower Tax Rate Expected in 2027After this year's special impacts are absorbed, management expects the effective tax rate to be significantly below 40% next year, with a range of 35% to 40% cited as a maximum expectation.
- Cannabis Market Expansion Under ConsiderationThe company is working on expanding the sales footprint of its cannabis products into additional geographies, although management said it will provide updates if these opportunities materialize.
DE:ILM1 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 31, 2027 | 2026 (Q4) | ―- | -0.19 | ― | ― |
| Nov 10, 2026 | 2026 (Q3) | 0.260.17 | 0.29 | -40.00% (-0.12) | |
| Aug 12, 2026 | 2026 (Q2) | ―0.14 | 0.3 | -51.67% (-0.15) | |
| May 12, 2026 | 2026 (Q1) | 0.220.44 | 0.25 | 76.00% (+0.19) | |
| Mar 26, 2026 | 2025 (Q4) | 0.34-0.19 | 0.08 | -324.10% (-0.27) | |
| Nov 11, 2025 | 2025 (Q3) | 0.260.29 | 0.16 | 83.54% (+0.13) | |
| Aug 13, 2025 | 2025 (Q2) | 0.250.30 | 0.18 | 66.67% (+0.12) | |
| May 13, 2025 | 2025 (Q1) | ―0.25 | 0.17 | 47.06% (+0.08) | |
| Mar 25, 2025 | 2024 (Q4) | 0.250.08 | 0.1 | -17.00% (-0.02) | |
| Nov 12, 2024 | 2024 (Q3) | ―0.16 | 0.3 | -46.98% (-0.14) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


